Med tech

Houston biotech company aims to enhance oncology treatment of highly resistant cancers

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat.

Klemp observed that while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he says. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

The company has three core technologies currently being tested with some success, but the most promising is called WP1066, named for researcher Waldemar Priebe, "a rock star" in his native Poland, according to Klemp, who works at MD Anderson. Though Priebe came to the U.S. in the 1980s, he is still an adjunct professor at the University of Warsaw and conducts some of his trials in Poland because it's easier to get grant money there.

WP1066 uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The molecular compound that Priebe discovered affects STAT3 (signal transducer and activator of transcription), a transcription factor that encourages tumor development. In short, the active compound in WP1066 both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

WP1066 is demonstrating drug-like properties in trials at MD Anderson on glioblastoma, the aggressive brain cancer that recently took the life of the hospital's former president, John Mendelsohn, as well as John McCain and Beau Biden. It is also being tested against pancreatic cancer, one of the most virulent killers cancer doctors combat.

Priebe also created Annamycin, named for his oldest daughter, a first-line chemotherapy drug that fights Acute Myeloid Leukemia without the cardiotoxicity that can damage patients' hearts even as they beat their cancer.

WP1122 uses yet another mechanism to fight cancer.

"Most people don't know that morphine is essentially a modified version of heroin," Klemp explains.

The difference between the poppy-based drugs? Heroin can cross the blood-brain barrier. It's described as the dicetyl ester of morphine. WP1122 is the dicetyl ester of 2DG (2-Deoxyglucose), a glycolysis inhibitor, which works by overfilling tumor cells with fake glucose so that they can't consume the real glucose that makes them grow.

"The theory is, we could feed you so full of junk food that eventually you'd starve to death," Klemp elucidates. It can cross the blood-brain barrier and is metabolized slowly, meaning that it can be made into a drug in a way that 2DG cannot.

What's impressive about Moleculin is its diversity of drugs. Most companies have one drug that gets all or most of the attention. Moleculin has strong hopes for all three currently in trials.

"It's essentially multiple shots on the goal," says executive vice president and CFO Jonathan Foster.

Moleculin has 13 total employees, five of whom are based in Houston. An office in the Memorial Park area serves as a landing pad for employees and collaborators from around the world to get their work done when in Space City. The virtual office set-up works for the company because experts can stay in their home cities to get their work done. And that work is on its way to saving scores of lives.

Trending News

Building Houston

 
 

The latest Houston innovation news includes a name for the burgeoning Texas A&M University campus in the Texas Medical Center. Photo courtesy of TAMU

Houston's innovation ecosystem has been booming with news, and it's likely some might have fallen through the cracks. From a Texas university naming its burgeoning new campus to a Houston SaaS startup with fresh funds, here are some short stories in Houston innovation.

ThoughtTrace raises $10M series B

ThoughtTrace has received investment from Chevron Technology Ventures. Photo via thoughttrace.com

ThoughtTrace Inc., a Houston-based software-as-a-service startup closed a $10 million series B round led by Canadian venture capital fund McRock Capital with contribution from Houston-based Chevron Technology Ventures.

"Chevron Technology Ventures (CTV) pursues externally-developed technologies and new business solutions that have the potential to enhance the way Chevron produces and delivers affordable, reliable and ever-cleaner energy," says Barbara Burger, president of CTV, in a release. "ThoughtTrace fits that mandate with the potential to automate the complex, time-consuming, and document-intensive workflows required for our ongoing business operations."

ThoughtTrace's software quickly analyzes documents and contracts and produces results at a fraction of the cost and time of traditional methods. With the fundraising deal, Scott MacDonald, McRock's co-founder and managing partner, will join ThoughtTrace's Board of Directors.

"We are extraordinarily excited to have both McRock and Chevron join the team. McRock brings a great background in the industrial space, which we see as a great fit. In the case of Chevron, they went from being a new customer in 2019 to an investor in 2020," says Nick Vandivere, ThoughtTrace CEO, in a release.

"With the new capital raise, ThoughtTrace will accelerate its investment in creating AI with unparalleled speed and accuracy, grow strategic partnerships and platform integrations, and add to its existing team of talented professionals, all of which will bring further value to the growing ThoughtTrace customer-base," Vandivere continues.

Texas A&M names its Texas Medical Center campus

The new campus will be called Texas A&M Innovation Plaza. Photo courtesy of Texas A&M University System

After announcing its plans for a $546 million medical complex in Houston's Texas Medical Center in February, Texas A&M University has released the name of the 5-acre campus rising at the intersection of Holcombe Boulevard and Main Street: Texas A&M Innovation Plaza.

The project will be completed in phases. The first phase, which will open later this year, is a renovation of an 18-floor building at 1020 Holcombe Blvd., which will to be the new home for EnMed, a dual degree program that produces both a master's in engineering and a medical degree.

"EnMed is just the first example of innovation that Texas A&M System intends to bring to the Texas A&M Innovation Plaza," says Chancellor John Sharp in a news release. "We are excited to have such a visible location in the Texas Medical Center."

Rice Business Plan Competition lays out virtual plans

The competition must go on. Photo via rbpc.rice.edu

This year's Rice Business Plan Competition, which was planned for March 26 to 28, was canceled due to COVID-19, but the Rice Alliance for Technology and Entrepreneurship has decided to offer up an alternative: A virtual RBPC. Forty two student teams will compete over three virtual events.

  • Elevator Pitch Competition on June 17 (Open to the public): Each team will deliver 60-second pitches.
  • Round 1 on June 18 (Open to startups and judges only ): Each team will deliver 10-minutes to pitch to a panel of judges followed by Q&A.
  • Live finals on June 19 (open to the public): The seven finalists will pitch to the judges, and following a round of questions from judges, the winners and prizes will be announced.

Two health care educational institutions team up for new program

Xavier University and Baylor College of Medicine have launched a collaborative medical track. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Louisiana's Xavier University and Baylor College of Medicine in Houston have joined forces to allow Xavier students a smooth transition into Baylor's graduate programs. Xavier students, including traditionally underrepresented minorities — according to a press release — will have the opportunity to apply for the program in November. Three students will be selected for the program, which facilitates acceptance into the medical school.

"Our commitment at Baylor College of Medicine to diversity and inclusion creates the best environment for success across our mission areas of healthcare, research, education and community outreach," says Dr. Paul Klotman, president, CEO and executive dean of Baylor College of Medicine, in the release. "This important collaboration with Xavier University will strengthen this commitment, and I look forward to welcoming students from this new partnership into the Baylor family."

Klotman continues to express how inclusiveness is a priority for BCM and for this partnership.

"We live in a world where healthcare is changing and evolving," says Dr. Anne McCall, provost and senior vice president for Academic Affairs at Xavier, in the release. "This partnership will further equip our students with the diverse tools and training that they'll need to foster equity in the medical field and compete on an international level."

University of Houston begins offering virtual tours for perspective students

Potential UH Cougars can get the 411 on campus via a virtual tour tool. Photo via uh.edu

Before COVID-19 sent everyone home and canceled gatherings, classes, and events across the world, the University of Houston was already working on a way for potential students to tour and learn more about the campus. Now, in light of the pandemic, UH has released this virtual tour offering complete with live interaction from UH student ambassadors.

"I'm really excited about the live component we just added because prospective students can ask questions just like during a face-to-face campus tour and that interaction is invaluable," says Mardell Maxwell, executive director of UH Admissions, in a release. "UH is so committed to access, and we see this as a great opportunity not only for students in Houston and Texas, but for those coming from out of state. We are opening up access to campus across the world."

Anyone can sign up for a tour online through the university's website.

Trending News